Hypofractionated radiotherapy for early glottic cancer: a retrospective interim analysis of a single institution
- Author:
Jeong Won LEE
1
;
Jeong Eun LEE
;
Junhee PARK
;
Jin Ho SOHN
;
Dongbin AHN
Author Information
- Publication Type:Original Article
- Keywords: Radiotherapy; Glottis; Radiation dose hypofractionation; Intensity-modulated radiotherapy
- MeSH: Carcinoma, Squamous Cell; Carotid Arteries; Follow-Up Studies; Glottis; Humans; Radiotherapy; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate
- From:Radiation Oncology Journal 2019;37(2):82-90
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the results of hypofractionated radiotherapy (HFX) for early glottic cancer. MATERIALS AND METHODS: Eighty-five patients with cT1-2N0M0 squamous cell carcinoma of the glottis who had undergone HFX, performed using intensity-modulated radiotherapy (IMRT, n = 66) and three-dimensional conformal radiotherapy (3D CRT, n = 19) were analyzed. For all patients, radiotherapy was administered at 60.75 Gy in 27 fractions. Forty-three patients received a simultaneous integrated boost (SIB) of 2.3–2.5 Gy per tumor fraction. RESULTS: The median follow-up duration was 29.9 months (range, 5.5 to 76.5 months). All patients achieved complete remission at a median of 50 days after the end of radiotherapy (range, 14 to 206 days). The 5-year rates for locoregional recurrence-free survival was 88.1%, and the 5-year overall survival rate was 86.2%. T2 stage was a prognostic factor for locoregional recurrence-free survival after radiotherapy (p = 0.002). SIB for the tumor did not affect disease control and survival (p = 0.191 and p = 0.387, respectively). No patients experienced acute or chronic toxicities of ≥grade 3. IMRT significantly decreased the dose administered to the carotid artery as opposed to 3D CRT (V₃₅, p < 0.001; V₅₀, p < 0.001). CONCLUSIONS: Patients treated with HFX achieved acceptable locoregional disease control rates and overall survival rates compared with previous HFX studies. A fraction size of 2.25 Gy provided good disease control regardless of SIB administration.
